Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2160372

FN1CCCCC1.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
MLYCD O95822 2/20 0.34
HPGD P15428 2/20 0.33
MEN1 O00255 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
DPP4 P27487 3/20 0.33
DPP7 Q9UHL4 2/20 0.33
HTT P42858 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CHRM2 P08172 3/20 0.31
CHRM4 P08173 3/20 0.31
CHRM5 P08912 3/20 0.31
CHRM1 P11229 3/20 0.31
CHRM3 P20309 3/20 0.31
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2263516 1.00 ALDH1A1 (0.35) ALDH1A1MLYCDHPGDMEN1TSHR
Trifluoroacetic Acid SCHEMBL2263517 1.00 ALDH1A1 (0.35) ALDH1A1MLYCDHPGDMEN1TSHR
Trifluoroacetic Acid SCHEMBL3552982 0.97 MLYCD (0.35) ALDH1A1MLYCDHPGDMEN1TSHR
Trifluoroacetic Acid SCHEMBL28608906 0.81 ALDH1A1 (0.38) ALDH1A1TSHR
Acetic Acid SCHEMBL28765994 0.79 FFAR3 (0.39) ALDH1A1HPGDMEN1KMT2AHTT
N-Methylpiperidine SCHEMBL2071509 0.78 ALDH1A1 (0.38) ALDH1A1MLYCDDPP4DPP7HTT
N-Methylpiperidine SCHEMBL2072770 0.78 ALDH1A1 (0.38) ALDH1A1MLYCDDPP4DPP7HTT
Trifluoroacetic Acid SCHEMBL1784444 0.78 ALDH1A1 (0.44) ALDH1A1MLYCDHPGDMEN1TSHR
Trifluoroacetic Acid SCHEMBL2265017 0.78 ALDH1A1 (0.38) ALDH1A1MLYCDDPP4DPP7HTT
N-Methylpiperidine SCHEMBL2071510 0.78 ALDH1A1 (0.38) ALDH1A1MLYCDDPP4DPP7HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470823-B2 Saturated bicyclic heterocyclic derivatives as SMO antagonists INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-06-25 US disclosed
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Instituto di Ricerche di Biologia Molecolare P. Ang 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS SMO, SHH, GLI1 ALDH1A1 1864/4885MLYCD 1022/4885HPGD 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.